You searched for "vascular"
Corporate M&A pace gathers momentum
Intensifying franchise competition, maturing product development pipelines and looming loss of exclusivity spur renewed merger and acquisition (M&A) activity in the ophthalmics sector. Rod McNeil reviews recent deals and related strategic developments. AbbVie to acquire Allergan in $63 billion mega-combination,...Microcatheter in the vertebral artery as a cause of branched retinal artery occlusion?
A 19-year-old male presented to eye casualty with a seven-day history of a ‘blurred patch’ in the left eye. The patient denied any other visual symptoms including flashes or floaters and there had been no change in visual symptoms in...
Cataract surgery in patients with Vogt-Koyanagi-Harada
This retrospective, interventional case series of 286 patients (408 eyes) assessed visual outcome and prognostic factors in patients with Vogt-Koyanagi-Harada (VKH) undergoing cataract surgery between September 2008 and December 2017. Two groups were reviewed. The first group (352 eyes) had...Initiatives in macular service provision
A report from Monitor in October 2015 identifies good practices that will realise most of the potential productivity gain in elective care available to NHS hospitals. These include: stratifying patients by risk and creating low-complexity pathways for lower-risk patients (tailoring...
Acetazolamide and CMO
The authors set out to analyse the effect of acetazolamide therapy on inflammatory cystoid macular oedema (CMO) as defined by change in central macular subfield thickness (CST), as well as its effect on visual acuity. A retrospective chart review was...
Correlation between anti-retinal antibodies and proliferative vitreoretinopathy (PVR)
The pathological basis of PVR is not clearly understood and there are no effective medications targeting this condition. This cross-sectional study looked at the possible association of anti-retinal antibodies with patients with PVR and retinal detachment (RD). Aqueous and vitreous...
Aflibercept, bevacizumab or ranibizumab for DMO
This is a two-year randomised clinical trial of 660 patients with visual acuity impairment from diabetic macular oedema (DMO) who were randomised to monthly injections of 2.0mg aflibercept, 1.25 mg bevacizumab or 0.3mg ranibizumab. Focal or grid laser was performed...
Using OCT to screen and monitor Alzheimer’s disease
Alzheimer’s disease (AD) is a neurodegenerative illness characterised by progressive decline in cognitive function. AD is the main cause of dementia worldwide. Over recent years researchers have strived to find biomarkers to diagnose AD, particularly in the early stages of...
AMD and visceral fat and pro-inflammatory factors
Several large studies have shown a positive relationship between age-related macular degeneration (ARMD) and high body mass index. The waist-hip ratio is also associated with development of early AMD. Visceral fat has a pro-inflammatory effect, which means it has an...
OCT use with macular retinoblastoma
The authors explore the use of portable hand-held spectral domain OCT (SD-OCT) in three eyes of three infants and young children with macular retinoblastoma. All were treated with chemotherapy and all had SD-OCT before and after treatment. The children were...
Ranibizumab for the treatment of age-related macular degeneration
This multicentre randomised prospective open label study compared 0.5 versus 2mg of ranibizumab in patients with submacular retinal pigment epithelial (RPE) detachment due to age-related macular degeneration. Four treatment regimens were used for the two strengths either monthly for 12...
